Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)

BACKGROUND: We evaluated the efficacy and safety of the nontaxane microtubule dynamics inhibitor eribulin plus the humanized anti-VEGF monoclonal antibody bevacizumab in a novel second-line chemotherapy scheme in HER2-negative metastatic breast cancer (MBC) patients progressing after first-line pacl...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:ESMO Open
Main Authors: De Angelis, C., Bruzzese, D., Bernardo, A., Baldini, E., Leo, L., Fabi, A., Gamucci, T., De Placido, P., Poggio, F., Russo, S., Forestieri, V., Lauria, R., De Santo, I., Michelotti, A., Del Mastro, L., De Laurentiis, M., Giuliano, M., De Placido, S., Arpino, G.
Format: Artigo
Jezik:Inglês
Izdano: Elsevier 2021
Teme:
Original Research
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7900694/
https://ncbi.nlm.nih.gov/pubmed/33601296
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.esmoop.2021.100054
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki